New Viennalab tests for Carbamazepine hypersensitivity

ViennaLab is now releasing two real-time PCR based assays (RealFast Assay) for genotyping HLA-A*31:01 and HLA-B*15:02 in patients with an indication for carbamazepine (CBZ) treatment.

Both HLA alleles are associated with carbamazepine-induced hypersensitivity reactions in Europeans and in many Asian populations. According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidlines, patients positive for HLA-A*31:01 or HLA-B*15:02 should not be treated with carbamazepine to reduce the risk of severe cutaneous adverse reactions.

All new ViennaLab HLA RealFast Assays (HLA-A3101, HLA-B1502, HLA-B27, HLA-B5701) will include a new separate negative control for data analysis.

To view the product brochure, click here.